

Amendment Tool

v1.8 30 April 2025

For office use

QC: No

Section 1: Project information

Short project title*:	The RECOVERY Trial			
IRAS project ID* (or REC reference if no IRAS project ID is available):	281712			
Sponsor amendment reference number*:	Substantial Amendment 37			
Sponsor amendment date* (enter as DD/MM/YY):	30 June 2025			
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	<p>We propose to make several updates:</p> <p>(i) Remove two COVID-19 treatment comparisons that have now closed, and update the protocol and ICF-PIS to reflect that fact that there are no COVID-19 comparisons remaining in the trial.</p> <p>(ii) Exclude patients who have recently received systemic corticosteroids from the corticosteroid comparisons</p> <p>(iii) Add several clarifications to the protocol, including some that were requested during previous UK/EU regulatory submissions</p> <p>(iv) Update adult and child ICF-PIS to improve readability and clarify trial procedures</p> <p>(v) Add details of all UK trial sites and PIs (RECOVERY had previously not been required to list study sites because it was a COVID-19 pandemic response trial)</p> <p>(vi) Change of RSI to the current version of the SmPC for the purpose of EU regulatory submission (there is no change in safety information relevant to trial participants)</p> <p>(vii) The source of trial funding has changed - the trial now longer has NIHR/UKRI funding and is supported by Flu Lab, a charity. This has no consequences for sites.</p>			
Project type (select):	Specific study			
	Research tissue bank			
	Research database			
Has the study been reviewed by a UKECA-recognised Research Ethics Committee (REC) prior to this amendment?:	Yes		No	
What type of UKECA-recognised Research Ethics Committee (REC) review is applicable? (select):	NHS/HSC REC			
	Ministry of Defence (MoDREC)			
Is all or part of this amendment being resubmitted to the Research Ethics Committee (REC) as a modified amendment (i.e. a substantial amendment previously given an unfavourable opinion)?	Yes		No	
Where is the NHS/HSC Research Ethics Committee (REC) that reviewed the study based?:	England	Wales	Scotland	Northern Ireland
	Yes	No	No	No
Was the study a clinical trial of an investigational medicinal product (CTIMP) OR does the amendment make it one?:	Yes		No	
EudraCT number* (if the study has a EudraCT number enter it here. If the study does not have a EudraCT number enter "N/A"):	2020-001113-21			
Was this clinical trial of an investigational medicinal product (CTIMP) processed under the CTIMP combined review service (formerly known as the Combined Ways of Working (CWOW) pilot)?:	Yes		No	
Did the study receive Pharmacy Assurance?:	Yes		No	
Was the study a clinical investigation or other study of a medical device OR does the amendment make it one?:	Yes		No	
Was the study a performance evaluation study of an In Vitro Diagnostic (IVD) medical device^ (including as a companion diagnostic in a clinical trial of an investigational medicinal product)?:	Yes		No	
Does the amendment make the study a performance evaluation study of an In Vitro Diagnostic (IVD) medical device^ (including as a companion diagnostic in a clinical trial of an investigational medicinal product)?:	Yes		No	
^ IVD medical devices are tests used on biological samples, such as tissues, blood or urine, to determine the status of a person's health. This may be a reagent, reagent product, calibrator, control material, kit, instrument, apparatus, equipment or system, whether used alone or in combination				
Did the study involve the administration of radioactive substances, therefore requiring ARSAC review, OR does the amendment introduce this?:	Yes		No	
Did the study involve the use of research exposures to ionising radiation (not involving the administration of radioactive substances) OR does the amendment introduce this?:	Yes		No	
Did the study involve adults lacking capacity OR does the amendment introduce this?:	Yes		No	

Does the study involve access to confidential patient information outside the direct care team without consent OR does the amendment introduce this?: (e.g. the study relies upon section 251 support in England and Wales, or equivalent in Scotland to set aside the common law duty of confidentiality)	Yes	No		
Does the study involve prisoners or young offenders who are in custody or supervised by the probation service OR does the amendment introduce this?:	Yes	No		
Does the study involve children OR does the amendment introduce this?:	Yes	No		
Did the study involve NHS/HSC organisations prior to this amendment?:	Yes	No		
Did the study involve non-NHS/HSC organisations OR does the amendment introduce them?:	Yes	No		
	England	Wales	Scotland	Northern Ireland
Lead nation for the study:	Yes	No	No	No
Which nations had participating NHS/HSC organisations prior to this amendment?	Yes	Yes	Yes	Yes
Which nations will have participating NHS/HSC organisations after this amendment?	Yes	Yes	Yes	Yes

Section 2: Summary of change(s)

What do you want to update?:	Project information
	New site/PI only

Please note: Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the Amendment Tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, click the "Add another change" box.

Change 1				
Area of change (select)*:	CTIMP IMP			
Specific change (select - only available when area of change is selected first)*:	Change of IMPs			
Further information: explain what the change is, why the change is being made and any possible impact on study participants/carers (free text - note that this field will adapt to the amount of text entered):	Two COVID-19 comparisons that have closed within this platform trial are being removed from the protocol and ICF-PIS. These are the sotrovimab and high-dose dexamethasone comparisons. The protocol and ICF-PIS have also been updated to remove most references to COVID-19, as there are no COVID-19 comparisons left in the trial.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? (please note that this answer may affect the categorisation for the change):	All		Some	
Remove all changes below				

Change 2				
Area of change (select)*:	Study Design			
Specific change (select - only available when area of change is selected first)*:	Inclusion/exclusion criteria - Minor change unlikely to affect safety or scientific value of study			
Further information: explain what the change is, why the change is being made and any possible impact on study participants/carers (free text - note that this field will adapt to the amount of text entered):	Additional exclusion criterion added to protocol appendix 2. Patients who have previously received systemic corticosteroids during their current illness are excluded from the two corticosteroid comparisons (influenza and community-acquired pneumonia). Patients who have an indication for treatment with systemic corticosteroids are already excluded, so we do not anticipate that this would affect many potential participants. This refinement to the exclusion criteria will ensure even clearer separation between the treatment arms with respect to corticosteroid use.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? (please note that this answer may affect the categorisation for the change):	All		Some	
Remove all changes below				

Change 3				

Area of change (select)*:	Study Documents
Specific change (select - only available when area of change is selected first)*:	Protocol - Substantial changes (e.g. affecting safety or the scientific value of the trial)
<p>Further information: explain what the change is, why the change is being made and any possible impact on study participants/carers (free text - note that this field will adapt to the amount of text entered):</p>	<p>Several clarifications and updates to the protocol, mostly in response to requests following UK/EU regulatory submissions:</p> <ul style="list-style-type: none"> - Throughout protocol, removal of two COVID-19 treatment comparisons that have closed - Throughout protocol, minor corrections, clarifications & updated references (see explanatory comments in tracked version) - Throughout protocol, removal of the term 'low-dose' in relation to corticosteroids, as requested during EU approval (it was thought this might cause confusion) - Table 1, updated to clarify existing eligibility criteria - Section 2, addition of trial design figure, as requested during EU approval - Section 2.1, clarification to eligibility, as requested by UK research ethics committee - Section 2.3, collection of routinely collected procalcitonin values at baseline (if available) - Section 2.6, clarification to administration of allocated treatment, as requested by UK ethics committee - Section 2.9, change of 'de-identified' to 'coded' in relation to data from withdrawn participants, as requested during EU approval - Section 6.7, clarification of data sharing plan, as requested during EU approval - Appendix 1, clarification to a sentence about the previous trials of corticosteroids, as requested by MHRA - Appendix 2, addition of new exclusion criterion for corticosteroid comparisons, described in Change 2 above - Appendix 5, update to members of trial committees - Appendix 6, India removed as a participating country, as it was not possible to open comparisons there - Appendix 6, additional EU countries have been added, and EU sites are now allowed to open the baloxavir comparison - Appendix 6, pregnant women ineligible for all comparisons in Indonesia, due to local requirements that make their recruitment impractical - New appendix 7 (schedule of assessments), as requested during EU approval - New appendix 8 (abbreviations), as requested during EU approval

Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? (please note that this answer may affect the categorisation for the change):	All		Some	
			Remove all changes below	

Change 4				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	Other significant change to study documents (e.g. information sheets, consent forms, questionnaires, letters) that can be implemented within existing resource in place at participating organisations - Please specify in the free text below			
<p>Further information: explain what the change is, why the change is being made and any possible impact on study participants/carers. In particular, please describe why this change can be implemented within the existing resource in place at the participating organisations (free text - note that this field will adapt to the amount of text entered)*</p>	<p>The adult and child ICF-PIS have been updated to remove references to COVID-19 comparisons and to aid readability following feedback from study staff and participants. Clarification of age/weight eligibility has been added to the child ICF-PIS. Details on how to contact the trial team following discharge have been added. Some information on data sharing from the privacy notice has been added to the ICF-PIS to make this clearer.</p>			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? (please note that this answer may affect the categorisation for the change):	All		Some	
			Remove all changes below	

Change 5	
Area of change (select)*:	Participating Organisations
Specific change (select - only available when area of change is selected first)*:	Addition of sites undertaking the same activities as existing sites

Further information: explain what the change is, why the change is being made and any possible impact on study participants/carers (free text - note that this field will adapt to the amount of text entered):	Details of all sites & PIs in the UK have been added to the CTA form for the first time and listed in the REC cover letter. RECOVERY had previously not been required to list these because it was a COVID-19 pandemic trial, but with the removal of COVID-19 treatments these details have now been added. The sites listed have been participating in RECOVERY since the start of the COVID-19 pandemic.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? (please note that this answer may affect the categorisation for the change):	All		Some	
Remove all changes below				

Change 6				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	IB, SmPC - Substantial changes (e.g. affecting the risk/benefit assessment; changing Reference Safety Information)			
Further information: explain what the change is, why the change is being made and any possible impact on study participants/carers (free text - note that this field will adapt to the amount of text entered):	<p>We would like to update the Reference Safety Information to the current baloxavir marboxil SmPC.</p> <p>This update is for the purpose of opening the baloxavir comparison in the EU, as we expect the EMA will require us to submit a current SmPC. Our current baloxavir marboxil RSI is the EU SmPC dated 2021-01-07, which we are replacing with EU SmPC dated 2025-06-02.</p> <p>There has been no change between SmPC versions in the safety information relevant to RECOVERY trial participants (who must be aged 12 years or over in this treatment comparison), so this does not require any changes to the UK participant materials.</p>			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? (please note that this answer may affect the categorisation for the change):	All		Some	
Remove all changes below				

Change 7				
Area of change (select)*:	Study Management			
Specific change (select - only available when area of change is selected first)*:	Funding arrangements - Changes that do not affect payments to participants/researchers/sites			
Further information: explain what the change is, why the change is being made and any possible impact on study participants/carers (free text - note that this field will adapt to the amount of text entered):	The previous NIHR/UKRI funding for the COVID-19 comparisons has now ended. The trial is now funded by the Flu Lab, a charity. This does not affect payments to researchers/sites. There are no payments to participants.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? (please note that this answer may affect the categorisation for the change):	All		Some	
Add another change				

Section 3: Declaration(s) and lock for submission

Declaration by the Sponsor or authorised delegate	
<ul style="list-style-type: none"> I confirm that the Sponsor takes responsibility for the completed amendment tool I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf 	
Applicant identification:	Sponsor
	Legal representative of the sponsor Person or organisation authorised by the sponsor
Organisation:	University of Oxford

Name [first name and surname]*:	Kate O'Neill
Address:	RGEA, Boundary Brook House, Churchill Drive, Headington, Oxford OX3 7GB
Telephone number:	
Fax number:	
Purchase Order (PO) number for MHRA invoicing:	H62017838
Email address*:	rgea.amend@admin.ox.ac.uk

Lock for submission

Please note: This button will only become available when all mandatory (*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

Lock for submission

After locking the tool, [proceed to submit the amendment online](#). The "Submission Guidance" tab provides further information about the next steps for the amendment.

Section 4: Review bodies for the amendment

Please note: This section is for **information only**. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

	Review bodies																	Category:	
	UK wide:						England and Wales:				Scotland:				Northern Ireland:				
	REC	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	HMPPS	HRA and HCRW Approval	REC (AWIA)	PBPP	SPS (RAEC)	National coordinating function	HSC REC	HSC Data Guardians	Prisons		National coordinating function
Change 1:	Y	Y				(Y)				(Y)				(Y)				(Y)	A
Change 2:	N	N				(Y)				(Y)				(Y)				(Y)	A
Change 3:	Y	Y				Y				(Y)				(Y)				(Y)	A
Change 4:	Y	N				Y				Y				Y				Y	C
Change 5:	N	N				(Y)				(Y)				(Y)				(Y)	New site
Change 6:	N	Y				(Y)				(Y)				(Y)				(Y)	C
Change 7:	N	N				(Y)				(Y)				(Y)				(Y)	C
Overall reviews for the amendment:																			
Full review:	Y	Y				Y				Y				Y				Y	
Notification only:	N	N				N				N				N				N	
Overall amendment type:	Substantial for review																		
Overall Category:	A																		